ArticleTalanta2025
Rapid and sensitive detection of wood smoke exposure biomarkers using europium fluorescent nanoparticle label/lateral flow immunoassay.
Article in Talanta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in biomarkers of benzene exposure and toxicity: From mechanistic insights to occupational health applications (Review).Molecular medicine reports · 2026Review
- Tumor Exposomics: A New Paradigm for Individualized Continuous Exposure Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Exposure to wood smoke is associated with various adverse health problems. Biomonitoring of smoke exposure-associated biomarkers provides accurate measurements of personally absorbed doses. As a specific metabolite of benzene, the quantitative measurement of S-phenylmercapturic acid (S-PMA) plays a vital role in evaluating human exposure to wood smoke. In this study, we developed an efficient lateral flow immunoassay (LFIA) approach for accurately and rapidly measuring S-PMA levels. Europium chelate nanoparticles (EuNPs) conjugated with purified polyclonal sheep anti-S-PMA antibodies were employed as the fluorescent detection probe. This work is based on a competitive immunoassay, where the target S-PMA competes with the immobilized antigen on the test lines for the limited antigen-binding sites on EuNP-conjugated antibodies. Due to this competition, the fluorescent intensity of the EuNPs is inversely proportional to the concentration of the target S-PMA in the sample, enabling quantitative measurement. Owing to the large Stokes shift, superior fluorescent brightness, and saturation of the EuNPs, S-PMA levels can be measured with a limit of detection of 0.32 ng/mL, a detectable range of 0.10-30 ng/mL, and a linear detection range of 0.25-30 ng/mL under optimized conditions. Stability testing revealed that the LFIA strips can be stored at room temperature for up to one year while maintaining excellent detection performance for S-PMA. These results demonstrate that the EuNP-based LFIA is a promising tool for accurate preclinical and point-of-care evaluation of wood smoke exposure. A major advantage of this approach is its ability to accurately analyze smoke biomarkers at anticipated low concentrations. The sensor system allows low-cost, rapid, and on-site data collection and quantification of wood smoke exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.